10-year results of NRG Oncology/NSABP B-42 trial

(NRG Oncology) In the updated results from NRG Oncology/NSABP B-42 trial through 10 years of observation, extending letrozole therapy for additional five years after five years of adjuvant endocrine therapy resulted in a statistically significant improvement in the 10-year disease-free survival (DFS) of postmenopausal women with hormone-receptor-positive breast cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news